View More
One-pill, once-daily combination superior to sofosbuvir plus ribavirin, with no cases of virologic failure in open-label phase III trial.
Use of shorter 12-week treatment regimen highly effective in patients with F3 disease.
Similar SVR24 rates in white patients vs black patients; SVR12 rate not affected by baseline RAVs in patients with genotype 1a HCV infection.
Low rates of discontinuation due to AEs, treatment-related serious AEs, and/or grade 3 and 4 lab abnormalities in this interim analysis.
Analysis finds 8-week regimen is underused, despite being highly effective in qualifying patients.
High SVR rates maintained across patient subgroups, including cirrhotic and treatment-experienced patients; adverse event rates similar to placebo.
Both 12-week and 16-week regimens of daclatasvir plus sofosbuvir plus ribavirin were well tolerated, even in cirrhotic, treatment-experienced patients usually considered difficult to treat.
No relapse in noncirrhotic patients regardless of inclusion of ribavirin; no relapse in cirrhotic patients with 16 weeks of treatment including ribavirin.
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270
Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.